| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 24,024 | 27,459 | 26,527 | 48,264 |
| Non-cash impairment charges | NaN | NaN | NaN | 5,328 |
| Depreciation and amortization | 12,448 | 12,891 | 12,830 | 45,605 |
| Amortization of debt issuance costs | 572 | 572 | 572 | 2,015 |
| Deferred income taxes | 3,659 | 3,838 | 2,171 | -4,879 |
| Foreign currency losses, net | -2,335 | 1,245 | 239 | -600 |
| Acquisition-related items | 0 | 839 | 1,117 | 5,679 |
| Stock-based compensation expense | 411 | 434 | 339 | 717 |
| Other | 534 | 351 | 474 | 1,643 |
| Accounts receivable, net | 4,776 | -2,333 | -11,366 | 55,208 |
| Inventories, net | 19,328 | 47,032 | 26,181 | 44,294 |
| Other current assets | 603 | -7,565 | 306 | 16,346 |
| Other assets | -579 | -271 | 105 | -1,572 |
| Accounts payable | -2,942 | 753 | -4,627 | 45,555 |
| Accrued expenses and other liabilities | 361 | 11,025 | -13,688 | 47,159 |
| Net cash provided by operating activities | 16,206 | 19,352 | 9,302 | 80,124 |
| Purchases of short-term investments | 13,000 | 11,522 | 12,504 | 14,000 |
| Maturities of short-term investments | 9,500 | 5,004 | 9,000 | 49,000 |
| Capital expenditures | 15,316 | 11,097 | 13,806 | 38,293 |
| Business acquisition, net of cash acquired | NaN | NaN | NaN | 286,529 |
| Other, net | -2,010 | -431 | 3,704 | -1,134 |
| Net cash used by investing activities | -16,806 | -17,184 | -21,014 | -288,688 |
| Revolving credit facility borrowings | 73,000 | 62,000 | 86,000 | 532,000 |
| Debt issuance costs | NaN | NaN | NaN | 10,377 |
| Revolving credit facility repayments | 65,000 | 70,000 | 58,000 | 621,000 |
| Proceeds from insurance premium financing and other short-term debt | NaN | NaN | NaN | 7,530 |
| Payments of long-term debt | 4,063 | 4,062 | 4,063 | 325,014 |
| Proceeds from long-term debt | NaN | NaN | NaN | 650,000 |
| Payments of insurance premium financing and other short-term debt | 1,369 | 2,054 | 2,738 | 6,556 |
| Dividends paid | 4,868 | 4,864 | 4,864 | 19,449 |
| Net cash (used) provided by financing activities | -2,300 | -18,980 | 16,335 | 207,134 |
| Effect of exchange rate changes on cash | 2,343 | -471 | 107 | -1,144 |
| Net decrease in cash and cash equivalents | -557 | -17,283 | 4,730 | -2,574 |
| Cash and cash equivalents at beginning of period | 55,486 | 72,769 | 68,039 | NaN |
| Cash and cash equivalents at end of period | 54,929 | 55,486 | 72,769 | NaN |
PHIBRO ANIMAL HEALTH CORP (PAHC)
PHIBRO ANIMAL HEALTH CORP (PAHC)